<DOC>
	<DOCNO>NCT01591070</DOCNO>
	<brief_summary>The purpose study determine whether proactive use 0.1 % tacrolimus ointment twice weekly keep adult facial SD remission reduce incidence exacerbation .</brief_summary>
	<brief_title>Proactive Treatment Tacrolimus Ointment Adult Facial Seborrheic Dermatitis</brief_title>
	<detailed_description>Seborrhoeic dermatitis ( SD ) common chronic papulosquamous dermatosis , affect 2 % 10 % adult population , mainly age 20 50 year male bias . The affected skin appear erythematous oedematous , cover yellow-brown scale , often accompany pruritus . It typically affect area contain sebaceous gland , particularly scalp , ear , face , chest , intertriginous area . SD chronic course , relapse common . Therefore , therapy direct toward reduce symptom aggravate factor SD , loosen removal scale crust , inhibition yeast colonization , control secondary infection , reduction erythema pruritus . Standard topical treatment SD include corticosteroid anti-mycotic medication . However , chronic use topical corticosteroid particularly face could result undesirable outcome , telangiectasia , atrophy , stria , peri-oral dermatitis , tachyphylaxis , early relapse discontinuation treatment . SD relapse prevention strategy yet establish , investigator suspect intermittent use tacrolimus ointment effective prevent SD relapse .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Seborrheic</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>least 18 year age diagnosis facial seborrhoeic dermatitis take systemic topical treatment facial seborrhoeic dermatitis within previous 4 week know allergy component tacrolimus ointment malignant neoplasm ; immunologic abnormality active infection definitive cutaneous finding erythroderma , acne , psoriasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Facial seborrhoeic dermatitis , tacrolimus</keyword>
</DOC>